カテゴリー： VacZine Analytics

CAR-T療法の世界市場

【英語タイトル】MarketVIEW: CAR-T therapies overview

VacZine Analyticsが出版した調査資料（VACZ712004）・商品コード：VACZ712004
・発行会社（調査会社）：VacZine Analytics
・発行日：2017年3月
・ページ数：※お問い合わせください。
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：製薬
◆販売価格オプション（消費税別）
Single UserUSD5,780 ⇒換算￥630,020見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
【レポートの概要】

CAR-T or Chimeric Antigen Receptor T cells are a sub component of Adoptive T Cell therapy (ACT) , a promising new treatment intervention for cancer. In ACT, a patient’s individual T cells are removed and manipulated so they have an increased capacity to fight cancer. The therapy is usually personalized (autologous) for a specific patient.
Chimeric antigen receptor T cells present hybrid receptors consisting of an antigen binding domain of an antibody (e.g. directed to CD19) fused to the T-cell receptor signalling domain. So far, the technology has undergone four generations of development, where second-generation approaches have shown remarkable responses in clinical studies. Complete remission in up to 90% of patients have been reported for relapsed or refractory B-cell Acute Lymphoblastic Leukaemia (B-ALL). Since 2015/2016 commercial interest has heightened in the development of CAR-T therapies with companies such as Novartis, Pfizer (Cellectis), Medimmune, Juno Therapeutics, and Kite Pharma involved in clinical studies, mainly against hematological cancers.

This MarketVIEW product consists of a product consists of a detailed Executive presentation (~91 slides) and MS-Excel work book summarizing latest developments in CAR-T therapies with a full review of the field to date. A searchable database of nearly 200 CAR trials has been compiled with analysis by start date, current phase, indication and sponsor type (industry and/or academic). For the hematological cancers, detailed case studies are provided looking at clinical trial parameters and data presented to date. Future perspectives, key risks, and challenges along with summary and conclusions are provided. This analysis is ideal for those wishing to gain an up-to-date understanding of the CAR-T landscape.

【レポートの目次】

Contents
Executive summary
Chimeric Antigen Receptors (CAR) – Background
Cancer Immunotherapy
Adoptive T cell therapy – T cells
Categories of adoptive T cell therapies
Adoptive T cell therapy – TIL approach
Adoptive T cell therapy – Genetically modified T cell approach
Adoptive T cell therapy – Genetically modified T cell approach – Engineered T cell receptor
Adoptive T cell therapy – Genetically modified T cell approach – Chimeric Antigen Receptor T cells (CAR-T)
Adoptive T cell therapy – Antigen selection for a CAR-T approach
CAR-T cell therapy – Potential issues and challenges
Chimeric Antigen Receptor T cells (CAR-T) – Review of Key Successful Clinical Trials
CAR-T cell therapy – successful clinical trials for CD19-CAR-T targeting acute lymphoblastic leukaemia
CAR-T cell therapy – successful clinical trials for CD19-CAR-T targeting lymphoma
Chimeric Antigen Receptors (CAR) – Current R&D pipeline
CAR-T Therapy – pipeline analysis methodology
Chimeric Antigen Receptor (CAR) Trials: total number of clinical trials
Chimeric Antigen Receptor (CAR) Trials: activity 2008-present
Chimeric Antigen Receptor (CAR) Trials: activity (industry)
Chimeric Antigen Receptor (CAR) Trials: activity (non industry)
Chimeric Antigen Receptor (CAR) Trials: phases and sponsor type
Chimeric Antigen Receptor (CAR) Trials: target indications (all phases)
Chimeric Antigen Receptor (CAR) Trials: phase I-IV, by indication
Chimeric Antigen Receptor (CAR) Trials: haematological indications, phases and sponsor type
Chimeric Antigen Receptor (CAR) Trials: multiple indications – phases and sponsor type
Chimeric Antigen Receptor (CAR) Trials: neurological indications – phases and sponsor type
Chimeric Antigen Receptors (CAR) – Advanced Clinical Trials for Blood Cancer Targets: Leukaemia/Lymphoma/Myeloma
Chimeric Antigen Receptor (CAR) Trials – haematological cancer targets
Blood cancer targets for CAR-T therapy: Leukaemia (background)
Leukaemia: survival rates and treatment types
Blood cancer targets for CAR-T therapy: Lymphoma (background) and survival rates
Lymphoma: current treatments
Blood cancer targets for CAR-T therapy: Myeloma (background), survival rates and current treatments
Advanced Clinical Trials for Leukaemia/Lymphoma/Myeloma
Leukaemia/Lymphoma/Myeloma – Industry sponsored CAR-T studies
Chimeric Antigen Receptors (CAR) – In depth review of key industry sponsored programmes
3 Contents available on request
2 Presentation titles may apply to more than one slide

Bluebird bio, Celgene Corporation: BB2121
Cellular Biomedicine Group Ltd: C-CAR011
Celyad: NKR2
Juno Therapeutics Inc, Celgene Corporation: JCAR017
Juno Therapeutics Inc, Celgene Corporation: other CD19+ trials
Juno Therapeutics Inc: CAR-T trials for additional targets
Juno Therapeutics, Inc., MedImmune LLC: JCAR014
Takara Bio Inc
Kite Pharma: KTE-C19
Novartis: CTL019
Novartis: CD19 CAR-T Long Term Follow Up
Servier, Cellectis, Pfizer: UCART19
Cellectis: additional UCARTS
CAR-T - summary and conclusions
Bibliography
About VacZine Analytics
Disclaimer
Slide number = 99

★調査レポート[CAR-T療法の世界市場] (コード：VACZ712004)販売に関する免責事項を必ずご確認ください。
★調査レポート[CAR-T療法の世界市場]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 癌治療ワクチンの世界市場
    VACZ712002 / VacZine Analytics / 2017年2月 / ...Cancer is one of the leading causes of death worldwide causing approximately 1 in every 7 deaths. In 2012, 8.2 million people died of the disease with 14 million new cases recorded in that year (WHO Figures). In 2030, the number of new cancer cases is projected to be >22 million (50-70% increase) due to the increasing population age and size. Cancer immunotherapy (active and passive) aims to harness the body’s own immune system in the fight against tumour progression. In the past decade, this strategy has become the most promising in the search for novel cancer therapies. Recent breakthroughs...
  • CAR-T r/r B-cell NHLの世界市場予測
    VACZ712009 / VacZine Analytics / 2017年8月 / ...Non-Hodgkin Lymphomas (NHLs) are a heterogeneous group of malignancies which have a wide range of histological appearances and clinical features. They are divided into two prognostic groups: Indolent lymphomas and Aggressive lymphomas. Of the B-cell type aggressive forms, Diffuse large B-cell lymphoma (DLBCL) and Follicular lymphoma (FL) are common types accounting for around 65% of cases (WHO figures). DLBCL is most common in people over 50 and has a current 5-year survival rate around 62%. It is estimated that approximately 26,000 people will be diagnosed with DLBCL in the United States in 2016. There are many treatment strategies for NHLs...
  • 単純ヘルペスウィルス(TX)ワクチンの世界市場
    VACZ712003 / VacZine Analytics / 2017年2月 / ...Herpes Simplex Virus (HSV-2) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging. Vaccine manufacturers have pursued the development of both prophylactic (PX) and therapeutic (TX) HSV vaccines albeit with little success to date. For therapeutic approaches a vaccine could reduce the frequency/duration of recurrences and lessen the need for long-term...
  • 単純ヘルペスウィルス(PX)ワクチンの世界市場
    VACZ712005 / VacZine Analytics / 2017年3月 / ...Herpes Simplex Virus (HSV-2) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging. Vaccine manufacturers have pursued the development of prophylactic (PX) HSV vaccines albeit with little success to date (note: GSK’s Simplirix). Mathematical modelling has indicated that mass vaccination with a HSV vaccine that can prevent the establishment of viral...
  • 日本脳炎ワクチンの世界市場
    VACZ712001 / VacZine Analytics / 2017年1月 / ...Japanese encephalitis (JE) is an enzootic mosquito-borne viral disease where humans are incidental “dead end” hosts. JE currently affects countries of SE Asia and Western Pacific where around 3 billion people are considered at risk. The disease mainly affects children (< 15yrs) in poor rural areas where it can result in 25% mortality (est 10,000 deaths/yr) or residual neuropsychiatric sequelae (30% of cases). There are no specific treatments for JE. Vaccines for JE have been available for decades and used in large scale routine immunization programs in South Korea, China and Japan. Older mouse brain derived vaccines are gradually being...
  • アシネトバクアターバウマニワクチンの世界市場
    VACZ712006 / VacZine Analytics / 2017年4月 / ...Acinetobacter baumannii of the Acinetobacter spp is a ubiquitous aerobic gram-negative bacillus which preferentially colonizes aquatic environments. Recently, the bacterium has become a "Priority No 1" pathogen primarily associated with hospital-acquired infections (HAIs). Patients usually affected are those critically ill having been admitted to the intensive care unit (ICU) and often receiving mechanical ventilation. In these instances A.baumannii related pneumonia can have high mortality rates of 50% or above. A.baumannii hospital infections can be difficult to treat with current antibiotics especially multidrug resistant forms MDR, XDR and PDR. In addition, such infections dramatically increase hospital length of stay (LOS) and...
  • ライノウイルス用ワクチンの世界市場
    VACZ712007 / VacZine Analytics / 2017年5月 / ...Human rhinovirus (HRV) is the major causes of the common cold. It can cause of morbidity in patients with chronic respiratory diseases, as well as infants and the elderly. In individuals with asthma, COPD and cystic fibrosis, HRV is associated with acute exacerbations that generate high healthcare costs largely due to hospitalizations. HRV also causes bronchiolitis in infants and respiratory illness in older adults. The treatment of HRV infection is primarily supportive, including over-the-counter products aimed at symptom relief. A broadly-protective HRV vaccine may have a significant public health impact if it could reduce or prevention of exacerbations in COPD...
  • 渡航者向けデング熱ワクチンの世界市場
    VACZ712008 / VacZine Analytics / 2017年7月 / ...Dengue Fever (DF) is a mosquito-borne disease (Aedes) caused by single strand RNA viruses of the family flaviviridae. It is is currently the second most common specific etiologic diagnosis among returned travelers with febrile illness after malaria globally. It is the most common febrile illness among travelers returning from Southeast Asia and South Central Asia. The disease not only poses a risk to the health of the individual traveler but is also a public health problem as returning viraemic travelers contribute to the spread of the disease. Dengue importation into vector infected areas has caused large numbers of autochthonous cases...

    • ◆H&Iグローバルリサーチのお客様（例）◆